Can we reveal the real you?

Österreich Sverige Suisse Schweiz Deutschland

Information About The Psoriasis Study

Participation in the Psoriasis Study will last for up to 19 months. This includes a 5-week screening period, a 12-week treatment period, a 40-week maintenance period, and a 24-week follow-up period.

All study participants will be divided into two treatment groups, one receiving the investigational medication, and the other receiving an approved medication for psoriasis (also referenced as the comparator).

This study has a blinded design. That means that neither the patient nor the physician who will evaluate psoriasis (or skin lesions) will be aware of the treatment that each patient will receive.

In this study each patient will receive subcutaneous (under the skin) injections with active drug (the investigational product or the comparator) and with placebo (contains no active ingredients).

The investigational product will be self-administered by the patient (or a caregiver). However, the injections for the comparator will be administered by the site staff during a visit. Since the syringes for the comparator and its placebo look different, the site personnel will be responsible for administering the comparator injections. The site personnel have been instructed to conceal the syringe which is used from each patient before, during and after the injection of the comparator.

Medications and therapies to avoid during this study

Key procedures and assessments

This visit-by-visit schedule lists key procedures that take place at each of the study clinic visits. The study site personnel can give you a rough idea about how long each visit should take.

Visit 1

Visit 2

Visit 3

Visit 4

Visit 5

Visit 6

Visit 7 and 8

Review and sign informed consent

Review medical history

Physical exam

Chest x-ray

Review current medications

Vital signs

Review pre-existing conditions/adverse events

Receive study medication

Questionnaires

ECG

Blood sample

Urine sample

Pregnancy test (for women of child bearing potential)

Visit 9

Visit 10 and 11

Visit 12

Visit 13 to 15

Visit 16

Visits 801 and 802 (V803 only if needed)

Review and sign informed consent

Review medical history

Physical exam

Chest x-ray

Review current medications

Vital signs

Review pre-existing conditions/adverse events

Receive study medication

Questionnaires

ECG

Blood sample

Urine sample

Pregnancy test (for women of child bearing potential)